

ADAPTED FROM WHO, UNAIDS, UNODC. 2009. TECHNICAL GUIDE FOR COUNTRIES TO SET TARGETS FOR UNIVERSAL ACCESS TO HIV PREVENTION, TREATMENT AND CARE FOR INJECTING DRUG USERS

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 1: NSP				
Does your programme offer NSP?	y/n			Distribution or exchange?
Does your programme direct beneficiaries to pharmacies to obtain needles and syringes?	y/n If no, please go on to the next intervention section Hr2			Comments: Are needles and syringes available at pharmacies? If so, are they affordable? How much do they cost?
Is there an estimate of the number of active IDUs in your coverage area?	y/n If yes, what is the estimate: Male/female:	Please provide details on data source		Comments on data source, quality and methodology for IDU population size estimate in your coverage area. If you do not have this data and information, please provide any ideas or opinions you have about the IDU population size in your coverage area.
Number of new IDU recruited	Total since the beginning of the project: Male/female: Total by year: Male/female			
Total number of contacts with clients Total number of IDU who have received services from your project	Total since the start of the project: Total by year (please give exact dates for your data): Male/female			
Number of IDUs regularly reached by your NSP service	Total number of IDUs reached regularly: Male/female:			How does your program define "reached regularly?" By WHO guidelines, "reached regularly" means "number of IDUs who accessed NSP once per month or more in the past 12 months." Can you provide data on number of IDUs who accessed NSP once per month or more in the past 12 months? If not, please explain why-e.g. the data has not been collected, the data has been collected but not analysed... If your project has been operating for less than one year, please give the number of regular clients for the past 4 months.

Full Template for Measuring IDU Service Coverage with Gender Considerations

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 1: NSP				
Number of IDUs reached by your NSP service in the past month	Total number of IDUs reached: Male/female:			
Does your NSP site adhere to WHO guidelines on NSP? (See Guide to starting and managing needle and syringe programmes WHO 2007 www.who.int/hiv/idu/Guide_to_Starting_and_Managing_NSP.pdf). Does your NSP site adhere to UNAIDS best practice recommendations for HIV prevention among IDUs? (See High Coverage Sites: HIV prevention among injecting drug users in transitional and developing countries: case studies Geneva UNAIDS 2006 data.unaids.org/publications/IRC-pub07./jc1254-highcoverageidu_en.pdf).				
Did you conduct a situation assessment about drug use in your area before beginning your NSP service?	If yes, please describe how you conducted your assessment and email any reports you have about your assessment together with this questionnaire. If not, please briefly explain why not. Did your assessment ask whether or not male IDU are married? Did you conduct a gender assessment of female drug use in your area before beginning your NSP service?			
How do you record your beneficiaries' attendance at your NSP services?	Please describe your system. Do you use a unique identifier code? Does your system allow you to determine the number of female and the number of male clients? Can your system differentiate among female injecting drug use, female non-injecting drug use, female who both inject and inhale drugs, and spouses of male drug users?			
Have you involved members of the IDU community in your assessment, planning and decision-making about the NSP?	Please describe. Were women members of the community involved in assessment, planning and decision-making about the NSP?			
Please describe your set-up: Are you operating a drop-in centre? Do you use outreach workers? What are your normal hours of operation?	How many of your program technical staff are women? Technical staff means staff who work directly with clients to offer services, not administrative staff. How many female clients do you have? What is the female technical staff: female client ratio? What is the male technical staff: male client ratio?			
Please describe any other services or products you provide together with NSP such as condoms, information etc.	Please provide precise details such as the usual number of condoms you provide (if you are providing condoms, the type of information materials, any referrals you may make to other services-such as VCT/HTC, etc.) How many of your on-site or referral services are gender-specific? Gender-specific services include reproductive health services such as antenatal care and gynaecological service, gender-based violence services, and childcare services and services for children.			
Do you have a usual number of needles and syringes you provide to each client?	Please provide details about how many needles and syringes you generally supply for each client, what size of needles and syringes you supply, what your approximate return rate is for used needles and syringes.			

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 1: NSP				
Total number of needles and syringes distributed per year	This is: number of syringes distributed in the past 12 months / number of IDUs in your coverage area Male/female			If you do not have the data for the past year, please provide the data you do have (for example past month)
Needles and syringes distributed per IDU per year				If you do not have this data, please provide the average number of needles and syringes that you provide to each IDU. Please describe any other materials you distribute to IDU at the same time as you distribute needles and syringes, such as information materials, condoms etc. Please be as specific as possible. For example, if you provide condoms together with the needles and syringes, indicate how many condoms on average.
Please use this space to describe any problems or challenges you have faced in setting up and running your NSP service (such a difficulties working with law enforcement etc.). Please also explain how you have worked to address these challenges.	Please describe any gender-specific challenges you have faced in setting up and running your NSP service, such as attracting and retaining female clients, or accessing the spouses of male IDU.			
HR Intervention 2: OST				
Does your programme offer OST?	y/n If no, please go on to the next intervention section HR 3			
Is there an estimate of the number of active IDUs in your coverage area?	y/n If yes, what is the estimate: Male/female:	Please provide details on data source		Comments on data source, quality and methodology for IDU population size estimate in your coverage area. If you do not have this data and information, please provide any ideas or opinions you have about the IDU population size in your coverage area.
Total number of IDUs who have accessed your project since it started	Total number: Male/female:			
Does your OST site adhere to WHO guidelines? (Guidelines for psychosocially-assisted pharmacological treatment of opioid dependence WHO 2009 www.who.int/substance_abuse/publications/opioid_dependence_guidelines.pdf and Operational guidelines for the treatment of opioid dependence in the South-East Asia Region WHO Regional Office for South Asia 2008 www.searo.who.int/LinkFiles/Publications_guidelines_management_opioid_in_SEAR.pdf).				

Full Template for Measuring IDU Service Coverage with Gender Considerations

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 2: OST				
Please describe the way in which you recruit clients.	How do clients enrol in your OST program? Where do you find them? How do they find you? Do you have requirements to determine who can enrol in your OST program (such as age requirements, requirements that clients have attempted to quit drugs in the past etc.), are clients required to take an HIV test in order to enrol in your OST program? Any other requirements?			
	Please describe any special efforts you make to attract and retain female clients to your OST program.			
Do you provide methadone or buprenorphine maintenance?	Which one?			
Please describe any other services you provide together with your OST programme.	For example referral to other services (which ones and please describe exactly how you offer referrals such as giving the name of a service provider, giving the phone number of a service provider, going together with the client to another service provider, giving the client a piece of paper with the contact information of another service provider etc.)			
	Please describe any gender-specific services you provide together with your OST programme.			
Does your OST programme provide psychosocial support?	Please provide details e.g. counsellor on site? How many counsellors? How many days per week? For how long each time (1 hour? All day?) Is it mandatory?			
	Please provide details about how many male and how many female counsellors you have on-site. What is the female counsellor: female client ratio? What is the male counsellor: male client ratio?			
How many people has your project put on OST since the project started?	Male/female			
How many people are on OST with your project now?	Number: Date: Male/female:			
How many opioid injectors (IDU) are on OST with your programme now?	Number: Date: Male/female:		Definition for an injector: a person who injected for non-medical purposes at least once in the past month	
How many of the people who are on OST now with your program have a maintenance dose of equal or greater than 60 mg methadone or 8 mg buprenorphine?	Number: Male/female:			
How many people currently on OST with your programme have been on OST continuously for the past 12 months?	Number: Male/female:			
What is the average duration of treatment on OST for your clients?	Male/female:			

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 2: OST				
What is the average maintenance dose of OST for your clients?	Male/female:			
Do you offer drug treatment options besides OST?				
HR Intervention 3: HIV Testing and Counselling HTC (VCT)				
Does your programme offer HTC for IDUs-either on-site or via referral?	On site y/n By referral y/n If both answers are "no" please go on to the next intervention section HR 4			
Is there an estimate of the number of active IDUs in your coverage area?	y/n If yes, what is the estimate: Male/female:	Please provide details on data source		Comments on data source, quality and methodology for IDU population size estimate in your coverage area. If you do not have this data and information, please provide any ideas or opinions you have about the IDU population size in your coverage area.
Total number of IDUs who have accessed your project since it started	Total number: Male/female:			
Total number of IDUs your project has referred to HTC since the project started	Total number: Male/female:			
Does your HTC site adhere to WHO guidelines? (Guidance on provider-initiated testing and counselling in health facilities Geneva WHO 2007 whqlibdoc.who.int/publications/2007/789241595568_eng.pdf and Guidance on testing and counselling for HIV in settings attended by people who inject drugs: improving access to treatment, care and prevention WHO Regional Office for the Western Pacific 2009 http://www.wpro.who.int/publications/PUB_9789290613985.htm)				
Please describe the method by which you provide HIV testing at your site	Do you provide VCT-clients attend your site with the purpose of getting an HIV test and they request the test when they arrive? Do you offer provider-initiated testing (PITC)-you offer the client the test before the client asks for the test? Is your PITC service opt-in-you inform clients that they have the opportunity to take an HIV test and the client decides whether or not to take the test? Is your PITC service opt-out-clients will be tested at your service unless they explicitly refuse? Is it mandatory?			
What kind of HIV test do you offer?	Express testing? How long do clients wait for their results? ELISA? Western blot?			
Please describe any other services you provide with HTC such as information material or referral to other service providers	Please indicate which services you provide referral to-such as CD4, ART, PMTCT, STI etc. Please indicate which services you provide referral to-antenatal care, parenting support, gender-based violence support, gynaecological service.			

Full Template for Measuring IDU Service Coverage with Gender Considerations

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 3: HIV Testing and Counselling HTC (VCT)				
Number of IDUs who received an HIV test at your programme (including referrals) since the programme began and know the results	Number of IDUs who received an HIV test: Male/female: Number of pregnant I/ DU women and number of spouses of male IDU who received antenatal testing and who know the result			
HR Intervention 4: Antiretroviral Therapy (ART)				
Does your programme offer or refer people who are active IDUs to ART? (i.e. being an active IDU is not an exclusion criteria for receiving ART)	y/n If no, please go on to the next intervention section HR 5			
Is there an estimate of the number of active IDUs in your coverage area?	y/n If yes, what is the estimate: Male/female:	Please provide details on data source		Comments on data source, quality and methodology for IDU population size estimate in your coverage area. If you do not have this data and information, please provide any ideas or opinions you have about the IDU population size in your coverage area.
Total number of IDUs who have accessed your project since it started	Total number: Male/female:			
Does your programme adhere to WHO guidelines on ART? (See HIV/AIDS treatment and care. Clinical protocols for the European Region Copenhagen WHO Regional Office for Europe 2006 www.who.int/hiv/topics/idu/care/E90840.pdf).				
Total number of IDU clients your programme has referred for ART	Total number: Male/female:			
Total number of clients whom you referred to ART who got ART	Total number: Male/female:			
Total number of pregnant I/ DU women your programme has referred for PMTCT				
Total number of pregnant I/ DU women your programme has referred for PMTCT who got PMTCT				

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 4: Antiretroviral Therapy (ART)				
Total number of pregnant spouses of male IDU your programme has referred for PMTCT				
Total number of pregnant spouses of male IDU your programme has referred for PMTCT who got PMTCT				
HR Intervention 5: Sexually Transmitted Infections (STI)				
Does your programme provide STI screening to IDUs either on-site or via referral?	On-site y/n By referral y/n			Symptomatic only? Or asymptomatic as well? Specify which STIs are screened for, and which are not screened for.
Does your programme provide STI treatment to IDUs either on-site or via referral?	On-site y/n By referral y/n If all your answers are "no" please go on to the next intervention section HR 6			Is treatment for some STIs offered on-site and for other STIs via referral? Please explain.
Is there an estimate of the number of active IDUs in your coverage area?	y/n If yes, what is the estimate: Male/female:	Please provide details on data source		Comments on data source, quality and methodology for IDU population size estimate in your coverage area. If you do not have this data and information, please provide any ideas or opinions you have about the IDU population size in your coverage area.
Total number of IDUs who have accessed your project since it began	Total number: Male/female:			
Total number of IDUs who have accessed your project in the past 12 months	Total number: Male/female:			
Does your programme adhere to WHO guidelines on STI screening and treatment? (See Guidelines for the management of sexually transmitted infections WHO 2003 www.who.int/hiv/pub/sti/en/STIGuidelines2003.pdf)				

Full Template for Measuring IDU Service Coverage with Gender Considerations

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 5: Sexually Transmitted Infections (STI)				
Does your programme provide case management?	The components of case management include: history taking, clinical examination, correct diagnosis, early and effective treatment, advice on sexual behaviour, promotion and/or provision of condoms, ethical partner notification and treatment, case reporting and clinical follow-up as appropriate. Please describe any of these components your programme provides.			
	Does your programme provide gender-specific case management for women clients?			
Does your programme provide counselling on STIs?	If so, please describe the counselling-who provides counselling, what are the key points the counsellor communicates to clients? Number of male counsellors? Number of female counsellors? Male counsellor: male client ratio: Female counsellor: female client ratio:			
Does your programme provide reproductive health services?	Such as antenatal care, infant care, abortion services?			
Number of IDUs attending your programme site who were screened for STIs in the past 12 months	Total number screened: Male/female:			
Number of IDUs at your programme who were diagnosed with an STI	Total number: Male/female:			
Number of IDUs at your programme who were diagnosed with an STI and received treatment in the past 12 months	Total number who received treatment in the past 12 months: Male/female:			
HR Intervention 6: Condom Programmes for IDU and their Sexual Partners				
Does your programme distribute condoms targeting IDUs and their sexual partners?	y/n If your answer is "no" please go on to the next intervention section HR 7			
Does your programme distribute female condoms targeting IDUs and their sexual partners?	y/n			
Is there an estimate of the number of active IDUs in your coverage area?	y/n If yes, what is the estimate: Male/female:	Please provide details on data source		Comments on data source, quality and methodology for IDU population size estimate in your coverage area. If you do not have this data and information, please provide any ideas or opinions you have about the IDU population size in your coverage area.

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 6: Condom Programmes for IDU and their Sexual Partners				
Total number of IDU clients your project has provided condoms to since the project began	Male/female:			
Total number of IDU clients who attended your programme in the past 12 months	Male/female:			
Does your programme adhere to UNFPA guidelines? (See Condom programming for HIV prevention: a manual for service providers New York UNFPA 2005 http://www.unfpa.org/hiv/programming.htm and Condom programming for HIV prevention: an operations manual from programme managers New York UNFPA 2005 http://www.unfpa.org/hiv/programming.htm)				
Please explain how you let potential clients know about your programme?	What is your advertising strategy? Do you have a sign to let clients know? A poster? Leaflets? Other mechanism? Please explain your choice of advertising strategy-why did you chose this particular strategy?			
Please comment on the quality and availability of condoms you provide.	Are you satisfied with the quality of condoms? Do you believe that clients are satisfied with the quality? Do you always have enough condoms? Have you experienced condom shortages? Please describe.			
Please describe any efforts you have made to promote a favourable attitude towards condoms	Examples might include: discussing HIV/AIDS and condoms with community groups, displaying and distributing promotional materials, using local entertainment forms to promote condoms, and persuading influential individuals and organisations to endorse condoms.			
Please describe condom support services you provide	Do you offer condom demonstrations? Do you provide counselling on condom negotiation (for example working with women to support them to negotiate condom use with their partners e.g. convince their husband to use a condom?)			
Total number of free condoms distributed per year by the programme (for the past 12 months)	Total number: Time period (indicate the exact dates): Distributed to men: Distributed to women:			If your program has been operating for less than one year, please write down the total number of condoms you have distributed so far, and indicate the exact dates-when you started distributing condoms, and the date on which you report the total number distributed, for example: "Between February 1 2010 and June 20 2010, we distributed 2,000 condoms." Are all the condoms distributed free of charge? Do clients have to pay for some of the condoms you provide? Any comments on condom quality?

Full Template for Measuring IDU Service Coverage with Gender Considerations

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 7: Targeted Information, Education and Communication (IEC) for IDU and their Sexual Partners				
Does your programme provide IEC for IDU?	y/n If your answer is "no" please go on to the next intervention section HR 8			
Does your programme provide targeted IEC for female IDU?	y/n			
Does your programme provide targeted IEC for the spouse of male IDU?	y/n			
Is there an estimate of the number of active IDUs in your coverage area?	y/n If yes, what is the estimate: Male/female:	Please provide details on data source		Comments on data source, quality and methodology for IDU population size estimate in your coverage area. If you do not have this data and information, please provide any ideas or opinions you have about the IDU population size in your coverage area.
Total number of IDU clients who attended your programme since it began	Please give exact dates Male/female:			
Total number of IDU clients who attended your programme in the past 12 months	Male/female:			
Does your programme adhere to WHO guidelines on targeted IEC for IDUs? (See Guide to starting and managing needle and syringe programmes WHO 2007 www.who.int/hiv/idu/Guide_to_Starting_and_Managing_NSP.pdf)				
Please describe how you provide information and education to IDU clients.	Do you offer opportunities for providing information and education during outreach? At a drop-in centre? Is this offered on a one-on-one basis? In group settings? Do you have a gender-specific strategy for accessing female IDU with IEC?			
Do you offer information and education on safe injection (good injection technique)?	Please describe. Do you have specific instruction on safe injection for women?			
Do you offer information and education on condoms?	Please describe. Do you provide gender-specific instruction for women on both male and female condoms?			
Do you provide overdose education?	Please describe Do you provide overdose education specifically geared to women?			

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 7: Targeted Information, Education and Communication (IEC) for IDU and their Sexual Partners				
How many different IEC materials for IDUs and/or sexual partners of IDUs has your programme developed? (e.g. one on VCT, one on OST...)				
How many of your IEC materials address gender-specific issues for women?				
Total number of targeted IEC materials that your programme distributed to IDU per year (in the past 12 months)	Total number: Number by type of IEC: Exact time period (please indicate the dates): Distributed to men: Distributed to women:			
HR Intervention 8: Diagnosis and treatment of and vaccination for viral hepatitis				
Is there an estimate of the number of active IDUs in your coverage area?	y/n If yes, what is the estimate: Male/female:	Please provide details on data source		Comments on data source, quality and methodology for IDU population size estimate in your coverage area. If you do not have this data and information, please provide any ideas or opinions you have about the IDU population size in your coverage area.
Does your programme offer vaccination for HAV on site or via referral?	On site y/n: Via referral y/n:			
Does your programme offer vaccination for HBV on site or via referral?	On site y/n: Via referral y/n:			
Does your programme offer HCV diagnosis on site or via referral?	On site y/n: Via referral y/n: If the answer to this question and the two questions above is "no" please go on to the next intervention section HR 9			
Total number of IDU clients who attended your programme since it began	Male/female:			
Total number of IDU clients who attended your programme since it began and tested positive for HAV	Male/female:			

Full Template for Measuring IDU Service Coverage with Gender Considerations

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 8: Diagnosis and treatment of and vaccination for viral hepatitis				
Total number of IDU clients who attended your programme since it began and tested positive for HBV	Male/female:			
Total number of IDU clients who attended your programme since it began and tested positive for HCV	Male/female:			
Does your programme adhere to guidelines on HAV/HBV vaccination? (See HIV/AIDS treatment and care. Clinical protocols for the European Region Copenhagen WHO Regional Office for Europe chapter 8 2006 (HAV/HAB vaccination) www.who.int/hiv/topics/idu/care/E90840.pdf)				
Does your programme offer treatment for HBV on site or via referral?	On site y/n: Via referral y/n:			
Does your programme adhere to guidelines on HBV treatment? (See HIV/AIDS treatment and care. Clinical protocols for the European Region Copenhagen WHO Regional Office for Europe chapter 7 2006 (HBV treatment) www.who.int/hiv/topics/idu/care/E90840.pdf)				
Number of clients referred for HBV vaccination since your programme began	Male/female:			
Number of clients who completed course of HBV vaccination since your programme began	Male/female:			
Number of clients diagnosed with and receiving treatment for HBV since your programme began	Male/female:			
Number of clients who completed treatment for HBV since your programme began	Male/female:			
Does your programme offer referral for HCV treatment?	y/n:			
Does your programme adhere to guidelines on HCV treatment? (See HIV/AIDS treatment and care. Clinical protocols for the European Region Copenhagen WHO Regional Office for Europe chapter 6 2006 (HCV treatment) www.who.int/hiv/topics/idu/care/E90840.pdf)				
Number of HCV-positive clients receiving treatment for HCV	Male/female:			
Number of clients who completed treatment for HCV	Male/female:			

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 9: Prevention, Diagnosis and Treatment of Tuberculosis (TB)				
Does your programme provide TB diagnosis and treatment services onsite or via referral?	On site y/n: Via referral y/n:			
Does your programme provide TB preventative therapy for clients?	y/n: If the answer to this question and the question above is "no" then please go on to the Outcome Indicators Section below.		Please provide details on data source	
Is there an estimate of the number of active IDUs in your coverage area?	y/n If yes, what is the estimate: Male/female:			Comments on data source, quality and methodology for IDU population size estimate in your coverage area. If you do not have this data and information, please provide any ideas or opinions you have about the IDU population size in your coverage area.
Does your programme adhere to WHO guidelines on TB prevention, diagnosis and treatment? (See Evidence for Action Technical Papers. Policy guidelines for collaborative TB and HIV services for injecting and other drug users-an integrated approach. Geneva WHO 2008. whqlibdoc.who.int/publications/2008/9789241596930_eng.pdf)				
Does your programme have a case-finding protocol for TB and HIV		A case finding protocol means that staff are aware of the symptoms of TB and HIV and can ensure that drug users have access to appropriate TB and HIV testing and counselling		
Does your programme provide information and education to staff so that they are aware of how to protect themselves from occupational exposure to HIV and TB.		Please describe.		
Please describe any challenges you have faced in your TB programme		Can active drug users have easy access to TB treatment? Do IDU who are HIV-positive have easy access to TB treatment? What are the challenges?		

Full Template for Measuring IDU Service Coverage with Gender Considerations

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Process and Output Indicators				
HR Intervention 9: Prevention, Diagnosis and Treatment of Tuberculosis (TB)				
Number of your programme IDU clients with TB status assessed since your programme began	Total number: Male/female:			
Number of IDUs in your programme who started on TB preventive therapy since your programme began	Total number: Male/female:			
Number of IDUs in your programme who completed TB preventive therapy since your programme began	Total number: Male/female:			
Number of IDUs in your programme who were diagnosed with TB and started on treatment since your programme began	Total number: Male/female:			
Number of IDUs in your programme who completed treatment for TB	Total number: Male/female:			

INDICATOR	DATA	DATA SOURCE	DATA QUALITY	COMMENTS AND RECOMMENDATIONS
Outcome Indicators				
Number of IDUs who attended your programme and report the use of sterile injecting equipment the last time they injected	Total Number: Male/female: Date your data was collected: Does not apply to my programme:			
Number of IDUs who attended your programme and can both correctly identify ways of preventing the parenteral transmission of HIV and who reject major misconceptions about parenteral HIV transmission (such as the belief that heroin kills the HIV virus)	Total Number: Male/female: Date your data was collected: Does not apply to my programme:			
Number of IDUs who attended your programme and report the use of a condom the last time they had sexual intercourse	Total Number: Male/female: Date your data was collected: Does not apply to my programme:			
Number of IDUs who attended your programme and can both correctly identify ways of preventing the sexual transmission of HIV and who reject major misconceptions about HIV transmission	Total Number: Male/female: Date your data was collected: Does not apply to my programme:			